

Chemical Science

rsc.li/chemical-science



ISSN 2041-6539



EDGE ARTICLE

Andreas Brunschweiler *et al.*

Acid- and Au(I)-mediated synthesis of hexathymidine-DNA-heterocycle chimeras, an efficient entry to DNA-encoded libraries inspired by drug structures

CrossMark
click for updatesCite this: *Chem. Sci.*, 2017, 8, 3356

Acid- and Au(I)-mediated synthesis of hexathymidine-DNA-heterocycle chimeras, an efficient entry to DNA-encoded libraries inspired by drug structures†

Mateja Klika Škopić, Hazem Salamon, Olivia Bugain, Kathrin Jung, Anne Gohla, Lara J. Doetsch, Denise dos Santos, Avinash Bhat, Bernd Wagner and Andreas Brunschweiler*

Libraries of DNA-tagged compounds are a validated screening technology for drug discovery. They are synthesized through combinatorial iterations of alternated coding and preparative synthesis steps. Thus, large chemical space can be accessed for target-based screening. However, the need to preserve the functionality of the DNA tag severely restricts the choice of chemical methods for library synthesis. Acidic organocatalysts, transition metals, and oxidants furnish diverse drug-like structures from simple starting materials, but cause loss of genetic information by depurination. A hexathymidine oligonucleotide, called "hexT" allows the chemist utilizing these classes of catalysts to access a potentially broad variety of structures in the initial step of library synthesis. We exploited its catalyst tolerance to efficiently synthesize diverse substituted β -carbolines, pyrazolines, and pyrazoles from readily available starting materials as hexT conjugates by acid- and Au(I)-catalysis, respectively. The hexT conjugates were ligated to coding DNA sequences yielding encoded screening libraries inspired by drug structures.

Received 30th January 2017
Accepted 27th February 2017

DOI: 10.1039/c7sc00455a

rsc.li/chemical-science

Introduction


DNA-encoded libraries (DELs) are mixtures of drug-like structures connected to individual DNA tags (1, Fig. 1A).¹ DNA tagging allows for sampling of large compound collections, and identification of bioactive compounds from these collections by selection, followed by amplification and sequencing of the genetic information. Screening of DELs against numerous target proteins from different protein families has provided several bioactive compounds, among them valuable tool compounds for chemical biology, and even clinical candidates.¹ Several DEL formats are actively used in drug discovery, namely DNA-recorded, DNA-templated, and DNA-routed libraries, DNA-encoded beads, and DNA-assembled fragment collections.² DELs are synthesized by combinatorial strategies through alternated coding and synthesis steps.^{1,2} Crucially, the latter must not compromise the integrity of the DNA tag.³ Thus, only a tiny fraction of the rich inventory of organic chemistry was heavily utilized for DELs: carbonyl chemistry, C–C cross-coupling reactions, substitution of halides, and "click" reactions.⁴ These are appendage reactions that couple building blocks to

appropriately functionalized structures. Due to the paucity in applicable synthesis methods DNA-encoded libraries show low variation in the connectivity of building blocks, they are heavily biased towards appendage diversity,⁵ and they require functionalized scaffolds to introduce topological diversity. Yet, the chemical space of bioactive compounds, synthetic compounds and natural products alike, contains a large variety of diversely substituted (hetero)cyclic structures.⁶ It has been argued that this structural wealth should be mirrored by screening libraries.^{7,8} An important access to structural diversity in compound libraries is the application of diverse synthesis methodology to build up molecules from simple starting materials. Currently, avenues to substituted (hetero)cyclic structures from simple starting materials are scarcely available for DEL synthesis: the Diels–Alder cycloaddition,⁹ condensation reactions,^{4c} and a class of spirocycles were reported.¹⁰ These reports show a lively interest in expanding the chemistry toolbox for DELs.^{1,4} Prolific sources of drug-like structures are Brønsted acid-, and coinage metal-catalyzed reactions.^{11,12} Yet, they cause depurination,^{13,14} and thus require the chemically much more stable PNA for encoding.^{16,15}

We hypothesized that a hexathymidine DNA "hexT" should be stable enough to allow tapping into the fields of acid- and coinage metal-catalysis to convert hexT-conjugates of simple starting materials 2 into hexT-heterocycle conjugates 3. Furthermore, the short hexT oligonucleotide had to be recognized by T4 ligase to record the synthesis step with coding DNA

Department of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 6, 44227 Dortmund, Germany. E-mail: andreas.brunschweiler@tu-dortmund.de

† Electronic supplementary information (ESI) available: Experimental procedures, compound characterization data, analysis of ligation reactions, and analysis of the tiDEL. See DOI: 10.1039/c7sc00455a






Fig. 1 Outline of the oligothymidine-initiated DNA-encoded chemistry (TiDEC) strategy. (A) Schematic presentation of a DNA-tagged compound, the coloured shapes represent partial structures of the compound; (B) the TiDEC concept to DNA-encoded libraries: (a) heterocyclic chemistry; (b) isolation of **hexT** conjugates; (c) DNA ligation; (C) exemplary drugs with TiDEC-accessible scaffolds. Filled black circle denotes controlled pore glass (CPG) solid support; bold bond denotes connection of the **hexT**-DNA to the CPG solid support; wavy bond denotes 5'-amino-PEG(4)-linker; het-cycle: heterocycle.

sequences (encoded compounds 4, Fig. 1B, "TiDEC", oligothymidine-initiated DNA-encoded chemistry).

In line with our hypothesis, we describe here the synthesis of **hexT**-conjugates of diverse substituted β -carbolines by the Brønsted acid-catalyzed Pictet-Spengler reaction,¹⁶ and the synthesis of **hexT**-conjugates of highly substituted pyrazol(in)es by a Au(I)-mediated cascade reaction^{17a} from simple, readily available starting materials. These scaffolds can be found in numerous bioactive compounds, among them natural products and drugs (Fig. 1C). The **hexT**-heterocycle conjugates could subsequently be ligated to coding DNA sequences by T4 DNA ligation, and expanded to combinatorial libraries.

Results and discussion

Ligation of the **hexT** oligonucleotide to coding DNA sequences

For DNA tagging of the heterocycles we chose T4 ligation of 5'-phosphorylated duplex DNA sequences with tetramer overhangs. T4 ligation is a validated, frequently used method to encode large compound libraries.^{2b,c} The DNA sequences were 5'-phosphorylated with polynucleotide kinase (PNK). Both Pictet-Spengler and the Au(I)-mediated cascade reaction efficiently

provide heterocycle formation and introduction of a substituent in one step. Thus, the **hexT** conjugates **I** were to be ligated to two enzymatically 5'-phosphorylated duplex DNAs **II** and **III** in one step, too (Fig. 1B and 2A-b); see Fig. S1 in the ESI† for a more detailed description of the encoding strategy, all sequences are given in Tables S1 and S2†: sequence **II** contained a hex-adenine overhang, forward primer, and heterocycle code; sequence **III** contained the substituent code (Fig. 2A-b). The ligation products were then in turn ligated to sequences **IV** coding for a set of building blocks that concluded library synthesis (Fig. 2A-c). We established the encoding strategy with the fluorescein-labeled **hexT-fluo** that facilitated detection of the ligation products (Fig. 2B, S3–S6†). Ligation of the very short hexamer oligonucleotide **hexT I** to a much longer duplex DNA **II** (30/40 mer) expectedly results in only a small shift of the migration of the ligation product compared to the non-ligated duplex, when detected by DNA staining (Fig. 2B, left hand trace (a)). A fluorescence scan unambiguously confirmed successful ligation of the **hexT** oligonucleotide **I** to a duplex DNA **II** (Fig. 2B, right hand trace (a)), and, as we required for our library synthesis design (Fig. 1B), to two double stranded DNA sequences **II** and **III** in one step (Fig. 2B-b). The product of the latter ligation experiment was precipitated, and ligated to a third duplex DNA **IV** (Fig. 2B-c). Besides the expected product which was formed in high yields we observed minor formation of longer ligation products. The ligation product at 100 bp might be explained by ligation of two fluorescein-labeled duplex-DNAs. T4 ligase is known for tolerance of mismatches in overhangs.¹⁸ The encoding strategy was confirmed by several ligation experiments with **hexT**-heterocycle conjugates that demonstrated the viability of TiDEC for the synthesis of




Fig. 2 Ligation of DNA sequences to **hexT**-fluo. (A) Ligation schemes; grey segments denote primer regions; black, blue and light red segments denote coding sequences; red star: fluorescein; PNK: polynucleotide kinase; (B) detection of ligation products by DNA stain (left hand trace (a)) and fluorescence scan (right hand trace (a) and (b and c)).

accordingly called tiDELs, oligothymidine-initiated DNA-encoded libraries (Fig. 2, S3–S11†).

Synthesis of hexT-β-carboline conjugates by acid-catalyzed Pictet–Spengler reaction


An essential structure in drug research is the β-carboline, constituting the core scaffold of the pharmacologically active natural product ajmalicine (5, Fig. 1C), the approved drug tadalafil (6, Fig. 1C), and drug candidates such as AZD9496 and the antimalarial NITD609. It can be accessed from tryptamines and aldehydes through the Brønsted acid catalyzed Pictet–Spengler reaction.¹⁶ We synthesized the controlled pore glass (CPG)-bound tryptophane conjugate **hexT-8** (Fig. S12 and S13†), and tested several conditions (Table 1, Fig. S14†) to react **hexT-8** with a 1000-fold excess of *p*-biphenylcarboxaldehyde **BO** (Table S3†) to the target β-carboline **hexT-9BO**.

It was readily obtained with 1% of trifluoroacetic acid in dry non-polar solvents CH₂Cl₂, toluene, and C₂H₄Cl₂, and in the polar, aprotic solvents DMF and acetonitrile overnight (Table 1, entries 1, 11, 14–16). The β-carboline was also formed with higher

concentrations of TFA in CH₂Cl₂, (up to 3% overnight, or 10% for four hours), 1% of trichloroacetic acid in CH₂Cl₂, 1% of diphenyl phosphate in CH₂Cl₂, and 50% of formic acid in CH₂Cl₂. The product of the Pictet–Spengler reaction was confirmed by comparison with the reference **ref-hexT-9BO** (Fig. S15†). Further investigation of the reagent scope revealed that the Lewis acids BCl₃ and BF₃ in CH₂Cl₂, and overnight treatment with 10% of TFA in CH₂Cl₂ degraded the oligonucleotide.

In the library synthesis, we used 2% of TFA in CH₂Cl₂ which gave quantitative conversion of the tryptophane to the

Table 1 Exploration of reaction conditions for the synthesis of the **hexT-β-carboline hexT-9BO**; (a) see table;^a (b) aq. NH₃/aq. MeNH₂. Wavy bond to **hexT** denotes 5'-amino-PEG(4)-linker, bold bond denotes connection to CPG solid support, filled circle denotes solid support




Entry	Catalyst	Solvent	Time [h]	Conversion ^b [%]
1	TFA (1–3%)	CH ₂ Cl ₂	18	100
2	TFA (10%)	CH ₂ Cl ₂	4	100
3	TFA (10%)	CH ₂ Cl ₂	18	— ^c
4	TCA (1%)	CH ₂ Cl ₂	18	100
5	(PhO) ₂ (HO)PO (1%)	CH ₂ Cl ₂	18	80
6	HCOOH (50%)	CH ₂ Cl ₂	4	100
7	BCl ₃ (1 N)	CH ₂ Cl ₂	18	— ^c
8	BF ₃ (1 N)	CH ₂ Cl ₂	18	— ^c
9	TFA (1%)	THF	18	0
10	TFA (1%)	Dioxane	18	0
11	TFA (1%)	DMF	18	60
12	TFA (1%)	DMF ^d	18	0
13	TFA (1%)	DMSO ^d	18	0
14	TFA (1%)	Toluene	18	100
15	TFA (1%)	C ₂ H ₄ Cl ₂	18	100
16	TFA (1%)	MeCN	18	100

^a 20 nmol **hexT-8**, 20 μmol **BO**, room temperature, dry solvent.

^b Estimated by HPLC analysis of the crude product. ^c Degradation of the DNA. ^d Solvent contained trace amounts of water.

Table 2 Exploration of reaction conditions for the synthesis of the **hexT-pyrazol(in)es hexT-14Y** and **-15Y**. (a) See table;^a (b) aq. NH₃/aq. MeNH₂. Wavy bond to **hexT** denotes 5'-C6-amino-linker; bold bond denotes connection to CPG solid support; filled black circle denotes CPG solid support



Entry	Conditions	Product ratio ^b [%]			
		14Y	15Y	16Y	17
1 ^c	A , THF, 50 °C	—	—	—	—
2 ^d	A , THF, 50 °C	15	—	55	—
3	A , THF, 50 °C	50	—	25	10
4	A , MeCN, 50 °C	75	—	25	—
5	A , C ₂ H ₄ Cl ₂ , 50 °C	40	—	10	50
6	B , AcOH, 50 °C	10	55	10	—
7	A , MeCN, 25 °C	—	—	—	—
8	A , MeCN, 60 °C	70	20	—	—
9	B , AcOH, 60 °C	<5	90	—	—
10 ^e	B , C ₂ H ₄ Cl ₂ , 50 °C	85	—	—	—
11 ^e	C , C ₂ H ₄ Cl ₂ , 50 °C	85	—	—	—
12	AgOTf, toluene, 50 °C	40	—	60	—

^a 30 nmol **hexT-12**, 30 μmol **Y**, 30 μmol **13**, 7.5 μmol **A** ([tris(2,4-di-*tert*-butylphenyl)phosphite]gold chloride)/AgSbF₆, **B** (PPh₃AuCl)/AgOTf, or **C** (chloro[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]-gold(i))/AgOTf, 18 h. ^b HPLC analysis of the crude, missing percentage to 100%: **hexT-12**. ^c 0.15 μmol **A**/AgSbF₆. ^d 1.5 μmol **A**/AgSbF₆. ^e 7.5 μmol AgOTf.



corresponding β -carboline with a 1000-fold excess of the carbonyl building blocks (aliquots of all reactions were analyzed by mass spectrometry). The Pictet–Spengler reaction revealed a broad scope with aliphatic, olefinic, heterocyclic, diverse aromatic aldehydes, and isatin furnishing 80 diversely substituted β -carbolines **hexT-9A-9CB**. The β -carboline displays a secondary amine, which lends itself to library expansion. However, in our hands this amine resisted amide bond formation efforts.^{4a} Fortunately, the introduction of a Boc-protected 2-aminoethyl group at the secondary amine of the β -carboline by reductive amination was facile on solid support (Fig. S14†).^{4c} All amine-substituted conjugates **hexT-10A-10CB** were cleaved from the solid support, and analyzed by analytical HPLC and MALDI-MS to ascertain their purity and identity. Indeed, 65 of the conjugates were obtained with a purity of >90%. The remainder were HPLC-purified. Inspection of the 15 products that had to be purified revealed that in all cases incomplete introduction of the aminoethyl group by reductive amination furnished a mixture of the β -carbolines **hexT-9** and the C2-linker-substituted compounds **hexT-10** (see Table S3†, and exemplary MALDI-MS spectra in the ESI†). The lipophilic Boc-group facilitated purification of the target compounds **hexT-10** by reverse phase HPLC. Finally, the Boc-group of each an aliquot of every compound **hexT-10** was removed with 10% of TFA in CH_2Cl_2 for six hours to provide 80 β -carbolines **hexT-11A-11CB** for further library synthesis (Fig. S14, Table S3†). These were again analyzed by MALDI-MS, which confirmed successful removal of the protective group, and stability of the **hexT** oligonucleotide under these reaction conditions.

Synthesis of hexT-pyrazol(in)e conjugates by a Au(I)-mediated cascade reaction

Many bioactive compounds, among them the former drug rimonabant (7, Fig. 1C), and the approved celecoxib represent highly substituted pyrazoles. A Au(I)-catalyzed cascade reaction provides access to the highly substituted pyrazolines from readily available alkynes, and azomethine imines that are formed *in situ* from aldehydes, and hydrazides (Table 2, Fig. S16†).^{17a} Pyrazolines can in turn be oxidized to pyrazoles under mild conditions. The CPG-bound alkyne **hexT-12**, isobutyric aldehyde **Y** and hydrazide **13** served to investigate the accessibility of the **hexT**-pyrazoline conjugates **hexT-14Y** by Au(I) catalysis. Systematic exploration of reaction parameters yielded four distinct, isolatable products in different ratios (Table 2, see Table S4 in the ESI† for an expanded version of Table 2, and Fig. S17–S22†): the pyrazoline **14Y**, the pyrazole **15Y**, the propargylamine **16Y**, and the hydration product **17**.

Performing the reaction with a 250 fold excess of the Au(I) catalyst **A**^{17b} versus **hexT-12** at 50 °C yielded a 2 : 1 : 0.4 mixture of pyrazoline **14Y**, propargylamine **15AJ**, and the hydration product **17** (Table 2, entry 3). Reducing the excess of the catalyst reduced the yield of **14Y** (entries 1 and 2),^{17a} and lowering the temperature to 25 °C returned only starting material (entry 7). Changing the solvent had a profound effect on the product ratio: MeCN yielded a 3 : 1 mixture of **14Y/16Y** (entry 4); 1,2-dichloroethane yielded a substantial amount of the hydration product **17** (entry 5); and running the reaction in glacial acetic

acid with catalyst **B** we observed formation of pyrazole **15Y** through ring closure, oxidation and Boc-group removal (entries 6 and 9). Finally, the triphenylphosphine- and N-heterocyclic carbene-based Au(I) catalysts **B** and **C**, respectively, yielded the pyrazoline as sole detectable product (entries 10 and 11).^{17a} Ag(I), which reportedly afforded propargyl amines by a Mannich-type reaction,^{17a} gave in our hands the ring-closed product **14Y** and the propargyl amine **16Y** in a 4 : 6 ratio, likely due to the high catalyst concentration (entry 12).

Prior to investigation of the scope of the reaction we synthesized reference compounds for the pyrazoline **14Y**, the pyrazole **15Y**, and the propargylamine **16Y** (Fig. S31†) and coupled these to the **hexT** by amide formation. Comparison of these authentic samples with **hexT-14Y-16Y** by HPLC confirmed formation of the proposed products (Fig. S23 and S24†). The pyrazole **hexT-15Y** was also accessed in stepwise manner *via* synthesis of pyrazoline **hexT-14Y**, acid removal of its Boc-group to **hexT-18Y**, and oxidation with DDQ (Fig. 3 and S25†). Thus, by control of reaction conditions the Au(I)-mediated cascade reaction provides two densely substituted core scaffolds, namely pyrazolines and pyrazoles, as **hexT**-conjugates from the same reactants for encoded library synthesis, thereby adding diversity to the projected screening library in a highly efficient manner.

Several unsymmetrically substituted hydrazides furnished the target heterocycles, besides the Boc-group also an acetyl group was tolerated (Table S5†). The benzyl-substituent could be substituted with electron-donating, and -withdrawing groups. Because these hydrazides have to be synthesized *de novo*, we decided to diversify the scaffold with readily available aldehydes, and introduce a position for further substitution by the amine-displaying hydrazide **19** (Fig. S26, Table S5†). The synthesis of 23 pyrazolines **hexT-20** and 48 pyrazoles **hexT-21** succeeded with branched aliphatic, and substituted benzaldehydes (Tables S6 and S7†), whereas linear aliphatic, and several heteroaromatic aldehydes did not give the expected product. In the first case the reaction failed likely due to a lack of reactivity of the azomethine imine intermediate, in the second case likely




Fig. 3 Diverse routes to **hexT**-pyrazole **15Y**; (a) **B** (see Table 2), AcOH, 60 °C, overnight; (b) aq. $\text{NH}_3/\text{MeNH}_2$, room temperature, 30 min; (c) **A** (see Table 2), MeCN, 50 °C, overnight; (d) DDQ/ CH_2Cl_2 ; (e) 10% TFA/ CH_2Cl_2 . R: *p*-aminocarbonylphenyl; wavy bond to **hexT** denotes 5'-C6-amino-linker; bold bond denotes connection to CPG solid support; filled circle denotes solid support.






Fig. 4 Synthesis of tiDELs based on β -carbolines, and pyrazol(in)es. Reagents and conditions: (a) 2% TFA/CH₂Cl₂, room temperature, overnight; (b) NaCNBH₄, 40 °C, overnight; (c) aq. NH₃/MeNH₂, room temperature, 30 min; (d) 10% TFA/CH₂Cl₂, 6 h; (e) A (see Table 2), MeCN, 50 °C, overnight; (f) B (see Table 2), AcOH, 60 °C, overnight; (g) T4 ligase, room temperature, overnight; (h) EDC, HOAt, DEAE sepharose, room temperature, overnight. R: *p*-aminocarbonylphenyl; wavy bond to hexT denotes 5'-amino-PEG(4)-linker.

due to poisoning of the metal catalyst. All pyrazol(in)es were HPLC-purified to provide authentic samples for the projected tiDEL (Fig. 4).

Synthesis of the oligothymidine-initiated DNA-encoded libraries

For synthesis of the oligothymidine-initiated DNA-encoded libraries (tiDELs), pmol-amounts of the in total 151 hexT-conjugates hexT-11, -20, and -21 were ligated in parallel to heterocycle-, and aldehyde-encoding DNA sequences with excellent yields (Fig. 4, S1 and S27A†). The ligation products were analyzed, and pooled by precipitation. The DNA pellet was then dissolved, split, and ligated to sequences containing the reverse primer, and genetic information for 96 carboxylic acids. These building blocks were taken from a previously published diversity set of carboxylic acids.¹⁸ We evaluated the reactivity of all members of this set with hexT-20Y or hexT-21Y, and selected those acids that gave the amide products with a yield of >80% (Table S8†).¹⁹

All encoded library constituents were transferred to DEAE sepharose in a 96 well plate, and reacted with the validated 96 carboxylic acids in parallel overnight.²⁰ Washing steps removed the excess of reagents, and elution of the DNA-conjugates with a high-salt buffer, followed by pooling, and desalting provided

a combined tiDEL with 14,496 compounds based on three scaffolds. The library was analyzed by gel electrophoresis, and PCR-amplified at two concentrations (Fig. S27B and C†). As *ca.* one percent of the library members contains the streptavidin binder desthiobiotin, the tiDEL was subjected to a streptavidin pull-down experiment *versus* a control DNA (Fig. S28†). PCR amplification indicated that a substantial part of the tiDEL was retained on the affinity matrix whereas only traces of the control DNA were detectable, suggesting the functionality of the tiDELs.

Conclusions

DNA-encoded libraries of small molecules are a validated technology for the identification of bioactive compounds.¹⁻⁴ They have recently been proposed as an open source screening tool for biologists, because the infrastructure for screening these libraries consists of little more than a magnet and a PCR thermocycler, and importantly DNA sequencing to read out the screening results is nowadays affordable.²¹ Yet, expanding the diversity of DNA-encoded small molecule libraries has been recognized a major challenge in the field.¹⁻⁴ We propose here a strategy to DNA-encoded libraries called TiDEC (oligothymidine-initiated DNA-encoded chemistry) that allows chemists to efficiently translate their creative synthesis methodology to these libraries, and thus make it accessible to biologists. Our herein described synthesis strategy relies on a hexathymidine DNA, hexT. HexT is recognized by T4 DNA ligase to record the synthesis with coding DNA, it is affordable in bulk, and displays a broad catalyst tolerance, *e.g.* acid and coinage metal catalysts that are well known to furnish diverse heterocycles – but are equally well known to cause DNA degradation. At the initial stage of library synthesis, the hexT-conjugates can be characterized by mass spectrometry and HPLC, and if necessary, be purified to provide authentic samples for library synthesis. Thus, also more complex reactions, such as multicomponent reactions that may give rise to side products can be utilized for DELs. We exploited the catalyst tolerance of the hexT to synthesize three exemplary drug scaffolds from simple, readily available starting materials as encodable hexT conjugates by acid catalysis, and a recently developed Au(i)-catalyzed transformation,^{17a} respectively. Notably, the β -carbolines hexT-11 and the pyrazolines hexT-20 display a substituent through an sp³-hybridized carbon, thus adding in stereochemical diversity, a feature that is not provided by most synthesis methods used in DEL synthesis. All hexT conjugates were characterized; if necessary, purified to ensure fidelity; recorded by DNA ligation; and diversified by amide coupling to yield a 14,496-membered tiDEL (oligothymidine-initiated DNA-encoded library) for drug screening. Our TiDEC strategy holds promise to make several catalytic strategies^{11,12} available for DNA-recorded libraries, and thereby expand their chemical space. It is likely compatible with other DEL formats that are successfully used in drug research, too.^{1,2}

Acknowledgements

This work was supported by the German Federal Ministry of Education and Research (BMBF) Grant 1316053.



References

- (a) S. Brenner and R. A. Lerner, *Proc. Natl. Acad. Sci. U. S. A.*, 1992, **89**, 5381–5383; (b) R. E. Kleiner, C. E. Dumelin and D. R. Liu, *Chem. Soc. Rev.*, 2011, **40**, 5707–5717; (c) N. Winssinger, *CHIMIA International Journal for Chemistry*, 2013, **67**, 340–348; (d) R. M. Franzini, D. Neri and J. Scheuermann, *Acc. Chem. Res.*, 2014, **47**, 1247–1255; (e) H. Salamon, M. Klika Škopić, K. Jung, O. Bugain and A. Brunschweiler, *ACS Chem. Biol.*, 2016, **11**, 296–307; (f) R. A. Goodnow Jr, C. E. Dumelin and A. D. Keefe, *Nat. Rev. Drug Discovery*, 2017, **16**, 131–147.
- (a) L. Mannocci, Y. Zhang, J. Scheuermann, M. Leimbacher, G. De Bellis, E. Rizzi, C. Dumelin, S. Melkko and D. Neri, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 17670–17675; (b) M. A. Clark, R. A. Acharya, C. C. Arico-Muendel, A. L. Belyanskaya, D. R. Benjamin, N. R. Carlson, P. A. Centrella, C. H. Chiu, S. P. Creaser, J. W. Cuzzo, C. P. Davie, Y. Ding, G. J. Franklin, K. D. Franzen, M. L. Geffer, S. P. Hale, N. J. Hansen, D. I. Israel, J. Jiang, M. J. Kavarana, M. S. Kelley, C. S. Kollmann, F. Li, K. Lind, S. Mataruse, P. F. Medeiros, J. A. Messer, P. Myers, H. O'Keefe, M. C. Oliff, C. E. Rise, A. L. Satz, S. R. Skinner, J. L. Svendsen, L. Tang, K. van Vloten, R. W. Wagner, G. Yao, B. Zhao and B. A. Morgan, *Nat. Chem. Biol.*, 2009, **5**, 647–654; (c) M. H. Hansen, P. Blakskjaer, L. K. Petersen, T. H. Hansen, J. W. Højfeldt, K. V. Gothelf and N. J. Hansen, *J. Am. Chem. Soc.*, 2009, **131**, 1322–1327; (d) D. R. Halpin and P. B. Harbury, *PLoS Biol.*, 2004, **2**, 1015–1021; (e) Z. J. Gartner, B. N. Tse, R. Grubina, J. B. Doyon, T. M. Snyder and D. R. Liu, *Science*, 2004, **305**, 1601–1605; (f) Y. Li, P. Zhao, M. Zhang, X. Zhao and X. Li, *J. Am. Chem. Soc.*, 2013, **135**, 17727–17730; (g) S. Melkko, J. Scheuermann, C. E. Dumelin and D. Neri, *Nat. Biotechnol.*, 2004, **22**, 568–574; (h) F. V. Reddavid, W. Lin, S. Lehnert and Y. Zhang, *Angew. Chem., Int. Ed.*, 2015, **54**, 7924–7928; (i) J.-P. Daguer, C. Zambaldo, M. Ciobanu, P. Morieux, S. Barluenga and N. Winssinger, *Chem. Sci.*, 2015, **6**, 739–744; (j) B. MacConnell, P. J. McEnaney, V. J. Cavett and B. M. Paegel, *ACS Comb. Sci.*, 2015, **17**, 518–534.
- M. L. Malone and B. M. Paegel, *ACS Comb. Sci.*, 2016, **18**, 182–187.
- (a) R. M. Franzini, F. Samain, M. Abd Elrahman, G. Mikutis, A. Nauer, M. Zimmermann, J. Scheuermann, J. Hall and D. Neri, *Bioconjugate Chem.*, 2014, **25**, 1453–1461; (b) A. L. Satz, J. Cai, Y. Chen, R. Goodnow, F. Gruber, A. Kowalczyk, A. Petersen, G. Naderi-Oboodi, L. Orzechowski and Q. Strebel, *Bioconjugate Chem.*, 2015, **26**, 1623–1632; (c) K. C. Luk and A. L. Satz, in *Handbook for DNA-Encoded Chemistry*, ed. R. A. Goodnow Jr, Wiley, New York, 2014, pp. 67–98; (d) R. M. Franzini and C. Randolph, *J. Med. Chem.*, 2016, **59**, 6629–6644.
- M. Feher and J. M. Schmidt, *J. Chem. Inf. Comput. Sci.*, 2003, **43**, 218–227.
- A. A. Shelat and R. K. Guy, *Nat. Chem. Biol.*, 2007, **3**, 442–446.
- S. L. Schreiber, *Science*, 2000, **287**, 1964–1969.
- S. Wetzler, R. S. Bon, K. Kumar and H. Waldmann, *Angew. Chem., Int. Ed.*, 2011, **50**, 10800–10826.
- F. Buller, L. Mannocci, Y. Zhang, C. E. Dumelin, J. Scheuermann and D. Neri, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 5926–5931.
- X. Tian, G. S. Basarab, N. Selmi, T. Kogej, Y. Zhang, M. Clark and R. A. Goodnow Jr, *Med. Chem. Commun.*, 2016, **7**, 1316–1322.
- (a) D. Parmar, E. Sugiono, S. Raja and M. Rueping, *Chem. Rev.*, 2014, **114**, 9047–9153; (b) D. Kampen, C. M. Reisinger and B. List, *Top. Curr. Chem.*, 2010, **291**, 395–456.
- (a) D. J. Gorin, B. D. Sherry and F. D. Toste, *Chem. Rev.*, 2008, **108**, 3351–3378; (b) N. T. Patil and Y. Yamamoto, *Chem. Rev.*, 2008, **108**, 3395–3442; (c) M. Rudolph and S. K. Hashmi, *Chem. Commun.*, 2011, **47**, 6536–6544.
- W. Bannwarth, *Chimia*, 1987, **41**, 302–317.
- N. D. Hadjiladis and E. Sletten, *Metal Complex–DNA Interactions*, Wiley-Blackwell, New York, 2009.
- D. Chouikhi, M. Ciobanu, C. Zambaldo, V. Duplan, S. Barluenga and N. Winssinger, *Chem.–Eur. J.*, 2012, **18**, 12698–12704.
- J. Stöckigt, A. P. Antonchick, F. Wu and H. Waldmann, *Angew. Chem., Int. Ed. Engl.*, 2011, **50**, 8538–8564.
- (a) Y. Suzuki, S. Naoe, S. Oishi, N. Fujii and H. Ohno, *Org. Lett.*, 2012, **14**, 326–329; (b) B. Wagner, W. Hiller, H. Ohno and N. Krause, *Org. Biomol. Chem.*, 2016, **14**, 1579–1583.
- K. Harada and L. E. Orgel, *Nucleic Acids Res.*, 1993, **21**, 2287–2291.
- M. Klika Škopić, O. Bugain, K. Jung, S. Onstein, S. Brandherm, T. Kalliokoski and A. Brunschweiler, *Med. Chem. Commun.*, 2016, **7**, 1957–1960.
- D. R. Halpin, J. Lee, S. J. Wrenn and P. B. Harbury, *PLoS Biol.*, 2004, **2**, E175.
- (a) S. Brenner and R. A. Lerner, *Angew. Chem., Int. Ed.*, 2017, **56**, 1164–1165; (b) L. H. Yuen and R. M. Franzini, *ChemBioChem*, 2017, **18**, 1–9.

